EP1575582A4 - Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique - Google Patents

Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique

Info

Publication number
EP1575582A4
EP1575582A4 EP02784400A EP02784400A EP1575582A4 EP 1575582 A4 EP1575582 A4 EP 1575582A4 EP 02784400 A EP02784400 A EP 02784400A EP 02784400 A EP02784400 A EP 02784400A EP 1575582 A4 EP1575582 A4 EP 1575582A4
Authority
EP
European Patent Office
Prior art keywords
treatment
combination therapy
myelodysplastic syndrome
acute leukemia
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02784400A
Other languages
German (de)
English (en)
Other versions
EP1575582A1 (fr
Inventor
Jay Marshall Feingold
Matthew Leigh Sherman
Mark Stanley Berger
Lance Howard Leopold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1575582A1 publication Critical patent/EP1575582A1/fr
Publication of EP1575582A4 publication Critical patent/EP1575582A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
EP02784400A 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique Withdrawn EP1575582A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (fr) 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique

Publications (2)

Publication Number Publication Date
EP1575582A1 EP1575582A1 (fr) 2005-09-21
EP1575582A4 true EP1575582A4 (fr) 2009-03-11

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02784400A Withdrawn EP1575582A4 (fr) 2002-11-06 2002-11-06 Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique

Country Status (10)

Country Link
EP (1) EP1575582A4 (fr)
JP (1) JP2006508119A (fr)
CN (1) CN1720044A (fr)
AU (2) AU2002348178A1 (fr)
BR (1) BR0215935A (fr)
CA (1) CA2504611A1 (fr)
CR (1) CR7804A (fr)
MX (1) MXPA05004711A (fr)
NO (1) NO20052009L (fr)
WO (1) WO2004043461A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (fr) * 2004-10-29 2006-05-11 Regents Of The University Of California Methode visant a accroitre l'elimination des cellules tumorales a l'aide de combinaisons d'agents antineoplasiques
EP1661584A1 (fr) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation
WO2007008479A1 (fr) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Traitement de patients atteints de cancer a l'aide d'un conjugue de calicheamicine et d'anticorps en combinaison avec du zosuquidar
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
PL2120568T3 (pl) * 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
WO2009075841A2 (fr) 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Procédés d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-méthoxy-4-(méthylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphtyridine-3-carboxylique pour le traitement de troubles hématologiques antérieurs
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (fr) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
WO2018234433A1 (fr) * 2017-06-22 2018-12-27 Les Laboratoires Servier Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées
CA3069558A1 (fr) * 2017-07-09 2019-01-17 Biosight Ltd. Polytherapie anticancereuse
EP3917397A4 (fr) * 2019-01-28 2022-10-26 Board of Regents, The University of Texas System Thérapie combinée à chélateur métallique pour le traitement de cancer
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
AU2021372482A1 (en) * 2020-10-27 2023-05-25 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012347A1 (fr) * 2000-08-08 2002-02-14 Immunomedics, Inc. Immunotherapie destine a traiter la leucemie myelocytique chronique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012347A1 (fr) * 2000-08-08 2002-02-14 Immunomedics, Inc. Immunotherapie destine a traiter la leucemie myelocytique chronique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AQUINO ET AL: "Acute myelogenous leukemia", CURRENT PROBLEMS IN PEDIATRICS, MOSBY, vol. 32, no. 2, 1 February 2002 (2002-02-01), pages 50 - 58, XP005008704, ISSN: 0045-9380 *
ERIC L. SIEVERS: "Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 46, 2000, pages S18 - S22, XP002513083 *
See also references of WO2004043461A1 *
TRAIL P A ET AL: "Monoclonal antibody drug conjugates in the treatment of cancer", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 11, no. 5, 1 October 1999 (1999-10-01), pages 584 - 588, XP004257589, ISSN: 0952-7915 *

Also Published As

Publication number Publication date
MXPA05004711A (es) 2005-08-03
NO20052009D0 (no) 2005-04-25
CN1720044A (zh) 2006-01-11
CA2504611A1 (fr) 2004-05-27
AU2002348178A1 (en) 2004-06-03
JP2006508119A (ja) 2006-03-09
NO20052009L (no) 2005-06-27
CR7804A (es) 2008-10-29
EP1575582A1 (fr) 2005-09-21
AU2010201113A1 (en) 2010-04-15
BR0215935A (pt) 2005-08-09
WO2004043461A1 (fr) 2004-05-27

Similar Documents

Publication Publication Date Title
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
EP1543034A4 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
SG104356A1 (en) Absorbent body and absorbent article having the absorbent body
GB0218526D0 (en) Combination therapy
HK1078784A1 (en) Therapeutic treatment
AU2003212634A8 (en) Compounds useful in the treatment of cancer
GB0223367D0 (en) Therapeutic treatment
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
GB0213869D0 (en) The treatment of pain
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
GB0207410D0 (en) Compounds and their therapeutic use
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0210464D0 (en) Therapeutic treatment
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
AU2002304883A1 (en) Device for the treatment of tumours

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075412

Country of ref document: HK

RAX Requested extension states of the european patent have changed

Extension state: SI

Payment date: 20050505

Extension state: RO

Payment date: 20050505

Extension state: MK

Payment date: 20050505

Extension state: LV

Payment date: 20050505

Extension state: LT

Payment date: 20050505

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEOPOLD, LANCE HOWARD

Inventor name: BERGER, MARK, STANLEY

Inventor name: SHERMAN, LEIGH, BERGER.

Inventor name: FEINGOLD, JAY, MARSHALL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEOPOLD, LANCE HOWARD

Inventor name: BERGER, MARK, STANLEY

Inventor name: SHERMAN, MATTHEW LEIGH

Inventor name: FEINGOLD, JAY, MARSHALL

A4 Supplementary search report drawn up and despatched

Effective date: 20090210

17Q First examination report despatched

Effective date: 20090731

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100827

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075412

Country of ref document: HK